methimazole + l-carnitine + selenium

A fixed combination of **methimazole**, **l-carnitine**, and **selenium** is used as a therapeutic regimen for the treatment of **Graves' disease** (autoimmune hyperthyroidism). Methimazole is an antithyroid agent that inhibits thyroid hormone synthesis by blocking thyroid peroxidase-mediated iodination; l-carnitine acts as a nuclear antagonist of thyroid hormone action, reducing thyrotoxicosis symptoms and potentially limiting hormone uptake and activity; selenium is an essential trace element with antioxidant and immunomodulatory properties that can enhance thyroid antioxidative protection and help modulate autoimmune responses. The combination aims to improve time to remission, reduce antibody titers (particularly TSH receptor antibodies), lower methimazole dosage requirements, and improve some hyperthyroid symptoms and overall patient quality of life[1][2][3][4].